Emily S Spivak1,2, Muriel Burk3,4, Rongping Zhang3, Makoto M Jones2,5, Melinda M Neuhauser4, Matthew Bidwell Goetz6,7, Francesca E Cunningham3,4. 1. Department of Medicine, Division of Infectious Diseases, University of Utah School of Medicine. 2. Veterans Affairs Salt Lake City Health Care System. 3. Center for Medication Safety. 4. VA Pharmacy Benefits Management Services, Hines, Illinois. 5. Department of Medicine, Division of Epidemiology, University of Utah School of Medicine, Salt Lake City. 6. Veterans Affairs Greater Los Angeles Healthcare System. 7. David Geffen School of Medicine at University of California, Los Angeles.
Abstract
BACKGROUND: Bacteriuria contributes to antibiotic overuse through treatment of asymptomatic bacteriuria (ASB) and long durations of therapy for symptomatic urinary tract infections (UTIs), yet large-scale evaluations of bacteriuria management among inpatients are lacking. METHODS: Inpatients with bacteriuria were classified as asymptomatic or symptomatic based on established criteria applied to data collected by manual chart review. We examined frequency of treatment of ASB, factors associated with treatment of ASB, durations of therapy, and frequency of complications including Clostridium difficile infection, readmission, and all-cause mortality within 28 days of discharge. RESULTS: Among 2225 episodes of bacteriuria, 64% were classified as ASB. After excluding patients with non-UTI indications for antibiotics, 72% of patients with ASB received antibiotics. When evaluating only patients not meeting SIRS criteria, 68% of patients with ASB received antibiotics. The mean (±SD) days of antibiotic therapy for ASB, cystitis, CA-UTI and pyelonephritis were 10.0 (4.5), 11.4 (4.7), 12.0 (6.1), and 13.6 (5.3), respectively. In sum, 14% of patients with ASB were treated for greater than 14 days, and fluoroquinolones were the most commonly used empiric antibiotic for ASB [245/691 (35%)]. Complications were rare but more common among patients with ASB treated with antibiotics. CONCLUSIONS: The majority of bacteriuria among inpatient veterans is due to ASB with high rates of treatment of ASB and prolonged durations of therapy for ASB and symptomatic UTIs. Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: Bacteriuria contributes to antibiotic overuse through treatment of asymptomatic bacteriuria (ASB) and long durations of therapy for symptomatic urinary tract infections (UTIs), yet large-scale evaluations of bacteriuria management among inpatients are lacking. METHODS: Inpatients with bacteriuria were classified as asymptomatic or symptomatic based on established criteria applied to data collected by manual chart review. We examined frequency of treatment of ASB, factors associated with treatment of ASB, durations of therapy, and frequency of complications including Clostridium difficile infection, readmission, and all-cause mortality within 28 days of discharge. RESULTS: Among 2225 episodes of bacteriuria, 64% were classified as ASB. After excluding patients with non-UTI indications for antibiotics, 72% of patients with ASB received antibiotics. When evaluating only patients not meeting SIRS criteria, 68% of patients with ASB received antibiotics. The mean (±SD) days of antibiotic therapy for ASB, cystitis, CA-UTI and pyelonephritis were 10.0 (4.5), 11.4 (4.7), 12.0 (6.1), and 13.6 (5.3), respectively. In sum, 14% of patients with ASB were treated for greater than 14 days, and fluoroquinolones were the most commonly used empiric antibiotic for ASB [245/691 (35%)]. Complications were rare but more common among patients with ASB treated with antibiotics. CONCLUSIONS: The majority of bacteriuria among inpatient veterans is due to ASB with high rates of treatment of ASB and prolonged durations of therapy for ASB and symptomatic UTIs. Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Christopher J Graber; Makoto M Jones; Matthew Bidwell Goetz; Karl Madaras-Kelly; Yue Zhang; Jorie M Butler; Charlene Weir; Ann F Chou; Sarah Y Youn; Matthew H Samore; Peter A Glassman Journal: Clin Infect Dis Date: 2020-08-22 Impact factor: 9.079
Authors: Melanie C Goebel; Barbara W Trautner; Yiqun Wang; John N Van; Laura M Dillon; Payal K Patel; Dimitri M Drekonja; Christopher J Graber; Bhavarth S Shukla; Paola Lichtenberger; Christian D Helfrich; Anne Sales; Larissa Grigoryan Journal: Am J Infect Control Date: 2020-05-08 Impact factor: 2.918
Authors: Haley J Appaneal; Aisling R Caffrey; Vrishali V Lopes; Christopher J Crnich; David M Dosa; Kerry L LaPlante Journal: Infect Control Hosp Epidemiol Date: 2019-07-29 Impact factor: 3.254
Authors: Jessica R Howard-Anderson; Shanza Ashraf; Elizabeth C Overton; Lisa Reif; David J Murphy; Jesse T Jacob Journal: Infect Control Hosp Epidemiol Date: 2020-01-30 Impact factor: 3.254
Authors: Barbara E Jones; Candace Haroldsen; Karl Madaras-Kelly; Matthew B Goetz; Jian Ying; Brian Sauer; Makoto M Jones; Molly Leecaster; Tom Greene; Scott K Fridkin; Melinda M Neuhauser; Matthew H Samore Journal: Med Care Date: 2018-07 Impact factor: 2.983
Authors: David M Jacobs; Thomas J Dilworth; Nicholas D Beyda; Anthony M Casapao; Dana R Bowers Journal: Antimicrob Agents Chemother Date: 2017-12-21 Impact factor: 5.191
Authors: Kimberly C Claeys; Min Zhan; Lisa Pineles; Alison Lydecker; Gosia Clore; Michihiko Goto; Surbhi Leekha; Darren Linkin; Charlesnika T Evans; Barbara W Trautner; Matthew B Goetz; Jonathan D Baghdadi; Eli N Perencevich; Daniel J Morgan Journal: Infect Control Hosp Epidemiol Date: 2020-08-25 Impact factor: 3.254
Authors: Haley J Appaneal; Theresa I Shireman; Vrishali V Lopes; Vincent Mor; David M Dosa; Kerry L LaPlante; Aisling R Caffrey Journal: BMC Geriatr Date: 2021-07-23 Impact factor: 3.921